|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L03AB07
|
|
gptkbp:brand
|
gptkb:interferon_beta-1a
|
|
gptkbp:CASNumber
|
220581-49-7
|
|
gptkbp:contraindication
|
hypersensitivity to interferon beta
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:form
|
solution for injection
30 micrograms once weekly
|
|
gptkbp:halfLife
|
10 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Avonex
|
|
gptkbp:indication
|
relapsing forms of multiple sclerosis
|
|
gptkbp:KEGGID
|
D02597
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Biogen
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
immunotherapy
|
|
gptkbp:MedlinePlusID
|
a696011
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:PubChem_CID
|
none
DB00060
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fatigue
headache
injection site reaction
flu-like symptoms
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:UNII
|
Q5JRX6B1F7
|
|
gptkbp:usedFor
|
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Biogen
|
|
gptkbp:bfsLayer
|
5
|